Vivet Therapeutics Email Format

Biotechnology ResearchÎle-de-France, France11-50 Employees

Vivet Therapeutics is a clinical-stage biotechnology company focused on developing gene therapies for rare inherited liver metabolic disorders. It aims to deliver durable treatment effects by advancing liver-directed gene delivery and long-term expression, collaborating with the Fundacion para la Investigacion Medica Aplicada (CIMA, Universidad de Navarra) to develop new AAV vectors targeting the liver and related technologies. Based in Paris, the company operates as a small to mid-sized team within the biotechnology research sector.

The firm has shared progress from its clinical and translational programs, including interim data from its Phase 1/2 GATEWAY trial of VTX-801 for Wilson disease, presented at the EASL Congress in 2024. More recently, in 2026, Vivet Therapeutics presented translational modeling data at ASGCT supporting its proprietary VTX-PID imlifidase formulation to enable AAV gene therapy in subjects with neutralizing antibodies. These activities reflect its position in the biotechnology landscape as a liver-targeted gene therapy developer focusing on orphan metabolic diseases.

Sign up for free to view info

Company overview Employee directory